key: cord-0961985-vuym41xv
authors: Liu, Anding; Li, Ying; peng, Jing; Huang, Yuancheng; Xu, Dong
title: Antibody responses against SARS‐CoV‐2 in COVID‐19 patients
date: 2020-06-30
journal: J Med Virol
DOI: 10.1002/jmv.26241
sha: 907c8b996a0cd01347395adf082964b3dc59e6a0
doc_id: 961985
cord_uid: vuym41xv

The emerging coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become a global pandemic, and brings formidable challenges to public health, society and the economy worldwide. Currently, the antibody responses against SARS‐CoV‐2 remains largely unknown. We herein estimated the longevity of specific antibodies against SARS‐CoV‐2, and reported that antibodies waned over substantially in COVID‐19 patients after recovery. This article is protected by copyright. All rights reserved.

Demographic data and clinical features were summarized ( Table 1 ). The median age of the studied patients was 61 years (interquartile range, 52-65 years), and 66.7% (28/42) were females. Among them, 14.3% (6/42) were in critical illness condition. The IgM antibody and IgG antibody against SARS-CoV-2 nucleoprotein and spike protein antigens in serum samples were measured using a commercially available magnetic chemiluminescent immunoassay assay (YHLO Biotech, Shenzhen, China) according to manufacturer's instructions 3 . The intraassay and inter-assay coefficients of variation for IgM are 5.4% and 8.7%

respectively, for IgG are 4.60% and 7.3% respectively. Serial serum samples were 

SARS-CoV-2: virus dynamics and host response